Intima Bioscience

Intima Bioscience is pioneering a novel approach to cancer immunotherapy by targeting the intracellular checkpoint protein CISH (Cytokine-Inducible SH2-containing protein), a key negative regulator of T-cell signaling. The company has advanced into clinical trials, with a first-in-human study (NCT04426669) using CRISPR-Cas9 to genetically engineer CISH-knockout tumor-infiltrating lymphocytes (TILs) in patients with metastatic gastrointestinal cancers, with initial data presented in 2025. Beyond cell therapy, Intima is developing a small molecule inhibitor platform against CISH, aiming for an orally available, off-the-shelf therapeutic. Its strategy positions it at the intersection of cutting-edge gene editing and traditional drug discovery to overcome limitations of current checkpoint inhibitors.

Dual-platform targeting the intracellular immune checkpoint CISH: 1) CRISPR-Cas9 gene editing for genetic validation and autologous cell therapy (CISH-knockout TILs), and 2) Discovery of small molecule inhibitors to disrupt intracellular protein-protein interactions, aiming for oral, off-the-shelf drugs.

Intima competes in the novel immune checkpoint space against companies targeting other next-generation surface checkpoints (e.g., TIGIT, LAG-3) and those developing enhanced cell therapies. Its unique angle is the focus on an intracellular target (CISH) and the parallel pursuit of both advanced cell therapy and small molecule modalities. Key competitors include large pharma immuno-oncology divisions and biotechs like Arcus Biosciences, iTeos Therapeutics, and numerous cell therapy companies.